skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Patient persistence with first-line antiglaucomatous monotherapy

Original Research

(2550) Views  (722) Full article downloads

Authors: Alfonso Arias, Konrad Schargel, Fernando Ussa, et al

Published Date April 2010 Volume 2010:4 Pages 261 - 267
DOI: http://dx.doi.org/10.2147/OPTH.S7971

Alfonso Arias1, Konrad Schargel2, Fernando Ussa3, Maria I Canut4, Amelia y Belén Robles4, Belén Martí Sánchez5

1Ophthalmology Department, Fundación Hospital Alcorcón, Madrid; 2Ophthalmology Department, Hospital de Torrevieja, Alicante; 3Instituto Universitario de Oftalmobiología Aplicada, Valladolid; 4Centro de Oftalmología Barraquer, Barcelona; 5Autónoma University of Madrid, Madrid, Spain

Purpose: To identify the extent of persistence (period of time of continuous therapy with the drug prescribed) of glaucoma patients treated with prostaglandins (latanoprost, bimatoprost, or travoprost), or β-blocker (timolol) monotherapy.

Methods: An observational retrospective study of a 24-month follow-up in 191 patients (from four centers) was done to identify the time elapsed until patients discontinued their antiglaucomatous treatment. The relevant information was extracted from patients’ medical charts. A descriptive analysis, a Kaplan–Meier survival analysis, and a Cox regression model were used to determine which drug was associated with greater patient persistence and to detect variables significantly influencing persistence.

Results: Descriptive analysis and survival curves showed that after 24 months, latanoprost was associated with a higher persistence in glaucoma treatment than the alternative agents: 81.6% versus 22.9% for bimatoprost, 65.4% for travoprost, and 60.5% for timolol (P < 0.0001). Persistence was significantly influenced by the antiglaucoma agent used as monotherapy (with a six-fold higher risk of treatment discontinuation during the follow-up period due to receiving bimatoprost instead of latanoprost; P < 0.0001) and patient age (P = 0.001). Even though comorbidities could not be directly related to persistence, their occurrence was related to patient age. The main reasons for treatment discontinuation were lack of efficacy, development of intolerance and/or adverse events, which were significant in the bimatoprost group, 28.6% (P < 0.001) and 48.6% (P < 0.001), respectively.

Conclusions: Latanoprost shows higher patient persistence compared with travoprost, bimatoprost, and timolol in routine clinical practice, and could lead to better control of intraocular pressure and lower associated economic costs.

Keywords: first-line monotherapy, glaucoma, treatment, persistence, Spain








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
Considerations in glaucoma therapy: fixed combinations versus their component medications
Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Importance of ivermectin to human onchocerciasis: past, present, and the future
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy